Frontlight ResearchEarly access
CompletedPhase 4
Effectiveness of N-Acetylcysteine (NAC) in Motivational Enhancement Therapy for Nicotine Addiction
Key facts
- Who runs it
- Universitas Indonesia
- Where
- Indonesia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 90 people enrolled
- Started
- 1 Jan 2023
- Ended
- 30 Dec 2023
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- n-acetylcysteine
- Motivational Enhancement Therapy
- Record updated
- 8 October 2024
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Male or female who are active smokers are at least 18 years old and decide to stop smoking
- Using tobacco cigarettes whether filtered or not
- Active smoker for at least 6 months
- Smoke at least 10 cigarettes per day
- Currently in the preparation or action stage at the stage of changes
- Able to follow instructions and research procedures
Who cannot take part
- Have/ suspected to have a systemic medical disorder or psychiatric disorder requiring acute management Currently using electronic cigarettes Currently using oral glucocorticoids Have an acute gastrointestinal ulcer Pregnant or breastfeeding or planning to become pregnant within the next 6 months Currently consume n-acetylcysteine Have a history of allergic reactions with n-acetylcysteine or its components Get therapy to stop smoking such as bupropion, varenicline or nicotine replacement therapy (NRT)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to determine the effectiveness of the combination of n-acetylcysteine and motivational enhancement therapy on laboratory improvement in the form of changes in blood nicotine, radiological changes in the form of nerve connectivity on post-therapy frontostriatal fMRI examination and clinical changes in the form of abstinence, withdrawal symptoms and cravings in adult smoker.
The 2 groups in the trial
- ExperimentalTreatment being tested
3600 mg NAC per day in 12 weeks
Treatment: n-acetylcysteine and Motivational Enhancement Therapy
- PlaceboPlacebo, for comparison
Treatment: Motivational Enhancement Therapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Effectiveness of N-Acetylcysteine in Motivational Enhancement Therapy for Nicotine Addiction: Study on the Dopaminergic Pathways, Changes in Functional Connectivity of fMRI Bold, and Changes in Smoking Abstinence
- Record updated
- 8 October 2024